Clinical Trial Registry

Trial Details for Trial MB102-020

Collaborator: AstraZeneca

Purpose: The purpose of this study is to evaluate the effects of dapagliflozin to promote glucose loss in urine in healthy subjects and subjects with type 2 diabetes mellitus

Overall Recruitment Status: Terminated

Condition(s): Diabetes Mellitus

Intervention(s): Dapagliflozin

Phase: Phase 1

Study Type: Interventional

Study Design: Allocation: Randomized,Endpoint Classification: Pharmacokinetics/Dynamics Study,Intervention Model: Parallel Assignment,Masking: Open Label,Primary Purpose: Diagnostic

Official Title: Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

Primary Outcome Measures:

  • The change in urinary glucose excretion dynamics
       Time Frame : after 7 days of treatment

  • Secondary Outcome Measures:
  • Differences in urinary glucose between healthy and diabetic subjects
       Time Frame : at 7 days
  • Changes in liver glucose production
       Time Frame : at one day
  • Glucose effects on tubular markers
       Time Frame : at one day

  • Arms Assigned Interventions
    Group 1:Active Comparator
    Subjects with T2DM - Dapagliflozin 5 mg
      Tablets, Oral, Once Daily, up to 29 days:
    Group 2:Active Comparator
    Subjects with T2DM - Dapagliflozin 20 mg
      Tablets, Oral, Once Daily, up to 29 days:
    Group 3:Active Comparator
    Healthy Subjects - Dapagliflozin 20 mg
      Tablets, Oral, Once Daily, up to 29 days:

    Estimated Enrollment: 1

    Study Start Date: June 2009

    Estimated Primary Completion Date: August 2009

    Download Date: processed this data on April 17, 2014

    Link Text: Link to the current record.



    Accepts Healthy Volunteers: Yes

    Minimum age: 18 Years

    Maximum age: 65 Years

    Gender(s): Both

    Criteria :
    Inclusion Criteria:

    • Male and female subjects
    • Age 18 to 65 years
    • BMI 18 to 35 kg/m2
    • Healthy subjects and subjects with type 2 diabetes mellitus on 1 of the following therapies: diet, sulfonylurea, and/or metformin
    • No evidence of impaired renal function
    Exclusion Criteria:
    • Unwilling or unable to use an acceptable method of birth control
    • Subjects with type 1 diabetes mellitus, heart disease, hepatic C or B
    • Exposure to insulin
    • Use of exclusionary concomitant medications
    • Evidence of significant kidney disease or any other significant medical or psychiatric disorder

    General Contact Information

    Clinical Trials that are no longer recruiting, have been completed or have been terminated will not display contact information ( facility contact, name and address of site location, etc.)

     More Information

         Investigator Inquiry form
    For FDA Safety Alerts and Recalls refer to the following link:

        Health Authority :   United States: Food and Drug Administration